Approval · Notice of Compliance 8336 · 2006
GEN-WARFARIN: Notice of Compliance 8336
Issued October 20, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8336
- Date
- October 20, 2006
- Company
- Genpharm Inc.Etobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- New strengths
- Therapeutic class
- Anticoagulant
- Canadian reference product
- COUMADIN (Dupont Merck Pharma Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GEN-WARFARIN | 02287498 | Cancelled Post Market |
| GEN-WARFARIN | 02287501 | Cancelled Post Market |
| GEN-WARFARIN | 02287528 | Cancelled Post Market |
Medicinal ingredients
- WARFARIN SODIUM 3 MG per TAB
- WARFARIN SODIUM 6 MG per TAB
- WARFARIN SODIUM 7.5 MG per TAB